deucravacitinib + alcohol

**Deucravacitinib + alcohol** refers to the co-administration of deucravacitinib, a selective and allosteric small molecule inhibitor of tyrosine-protein kinase TYK2, and ethanol (alcohol). Deucravacitinib is primarily developed and indicated for the treatment of moderate-to-severe plaque psoriasis. Its mechanism of action involves binding to the regulatory (pseudokinase) domain of TYK2, blocking signal transduction of cytokines involved in immune and inflammatory responses, notably IL-23, IL-12, and type I interferons. There is no reported pharmacokinetic or clinically significant interaction between deucravacitinib and alcohol. However, alcohol may trigger or worsen psoriasis symptoms in susceptible individuals, so patients with psoriasis are sometimes advised to moderate alcohol intake for disease management reasons, not due to a direct drug interaction[1][2][3][4][5].